文献速递消化道肿瘤放疗放疗物理与技术

肝细胞癌精准放疗:功能性肝脏避让计划的临床效用探索

Precision Radiation Therapy for Hepatocellular Carcinoma: Exploring the Clinical Utility of Functional Liver Avoidance Planning.
PubMed 文献 · Pract Radiat Oncol · 2026-04-04

本研究评估功能性肝脏避让计划(FLAP)在肝细胞癌放疗中满足临床约束并降低功能性肝组织剂量的效用。20例肝硬化程度不等的患者接受99mTc硫胶体SPECT/CT生成功能性肝脏体积(FLV),常规SBRT和PBT计划若未满足FLV剂量约束则进行FLAP再优化。FLAP再优化使FLV平均剂量中位降低13%,FLV V20中位降低4%。

要点

  • FLAP再优化使FLV平均剂量中位降低13%,FLV V20中位降低4%。
  • CP-B/C的SBRT计划40%需再优化,CP-A的PBT计划40%需再优化。
  • 既往肝脏定向治疗可能性越高,FLAP再优化频率越低(Spearman R=-0.95,P=.05)。

核心结论

  • 功能性肝脏避让计划作为保护肝功能、减轻肝毒性的规划策略,在不同肝细胞癌患者组中具有临床效用。

研究设计与样本

  • 20例年龄52-83岁(6例女性)、Child-Pugh评分A5-B9的肝硬化患者,接受99mTc硫胶体SPECT/CT成像生成30%max阈值的功能性肝脏体积(FLV)。
  • FLV配准至计划CT,半数患者既往接受过肝脏定向治疗(LDT)。
  • 生成容积调强弧形放疗-SBRT(5次,5例CP-A,5例CP-B/C)常规计划并按ASTRO共识指南优化。
  • 未满足已发表FLV剂量约束(FLV平均剂量、FLV V20)的计划进行FLAP再优化并缩放至相同靶区覆盖。
  • 类似生成扫描质子束治疗(PBT)计划用于大分割方案(15次,5例CP-A,5例CP-B/C)。

主要发现

  • CP-A患者的SBRT常规计划满足所有临床和功能性肝脏剂量约束。
  • 40%的CP-B/C SBRT计划、40%的CP-A PBT计划和80%的CP-B/C PBT计划需要针对FLV剂量约束进行再优化。
  • 与常规计划相比,FLAP再计划使FLV平均剂量中位降低13%(范围2%-30%),FLV V20中位降低4%(范围1%-10%)。
  • 既往LDT可能性增加与FLAP再优化频率降低相关(Spearman R=-0.95,P=.05)。
  • CP-A SBRT患者(80%既往LDT,0% FLAP再计划)比CP-B/C PBT患者(10%既往LDT,80% FLAP再计划)需要更少的功能性肝脏避让再计划。

关键数值与推荐

  • FLV在30%max阈值下生成。
  • SBRT为5次分割,PBT为大分割15次分割。
  • 功能性肝脏剂量约束包括FLV平均剂量和FLV V20。

临床怎么用

  • 对肝硬化程度较重(CP-B/C)或接受PBT的患者,FLAP再优化更常需要用于满足FLV剂量约束。
  • FLAP可降低功能性肝脏的平均剂量和V20,可能有助于保护肝功能并减轻肝毒性。
  • 既往接受过LDT的患者可能较少需要FLAP再优化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We assessed the utility of functional liver avoidance planning (FLAP) to meet clinical constraints and reduce dose to functioning liver tissue. METHODS AND MATERIALS: Twenty patients (aged 52-83 years, 6 women) with varying degrees of cirrhosis (Child-Pugh [CP] scores A5-B9) underwent [99mTc] sulfur colloid single-photon emission computed tomography/computed tomography imaging with generation of functional liver volumes (FLV) at 30%max thresholds, and FLV were coregistered onto planning computed tomography scans. Half of the patients received prior liver-directed therapy (LDT). Volumetric modulated arc therapy-stereotactic body radiation therapy (SBRT) (5 fractions, 5 CP-A, 5 CP-B/C) conventional plans were optimized following American Society for Radiation Oncology consensus guidelines, and those that did not meet published functional liver dose constraints (FLV mean, FLV V20) were reoptimized for functional liver avoidance and scaled to the same target dose coverage. Scanning proton beam therapy (PBT) plans were similarly generated for hypofractionated regimens (15 fractions, 5 CP-A, 5 CP-B/C). We characterized the associations between clinical characteristics and the probability of FLAP reoptimization and correlations with FLV dose reduction. RESULTS: SBRT conventional plans for CP-A patients met all clinical and functional liver dose constraints, whereas 40% of CP-B/C SBRT plans, 40% of CP-A PBT plans, and 80% of CP-B/C PBT plans required reoptimization for FLV dose constraints. Compared with conventional plans, FLAP replans achieved a median reduction of 13% (range, 2%-30%) in FLV mean dose and 4% (range, 1%-10%) in FLV V20. Increasing likelihood of prior LDT correlated with a decrease in FLAP reoptimization frequency (Spearman R = -0.95, P = .05). This was reflected in CP-A SBRT patients requiring fewer functional liver avoidance replans (80% prior LDT, 0% FLAP replans) compared with CP-B/C PBT patients (10% prior LDT, 80% FLAP replans). CONCLUSIONS: We successfully investigated the clinical utility of functional tissue avoidance in different groups of patients with hepatocellular carcinoma as a planning strategy to preserve liver function and mitigate hepatoxicity.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Yorke AA, Nyflot MJ, Apisarnthanarax S, et al. Precision Radiation Therapy for Hepatocellular Carcinoma: Exploring the Clinical Utility of Functional Liver Avoidance Planning. Pract Radiat Oncol. 2026. PMID: 41941894. doi:10.1016/j.prro.2026.03.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。